Carlos Lopez compensation by year
Niagen Bioscience Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $135,385 | $320,000 |
| Bonus | $0 | $0 |
| Stock awards | $0 | — |
| Option awards | $159,928 | $77,985 |
| Non-equity incentive | $49,798 | $150,656 |
| Pension and deferred compensation | $0 | $0 |
| All other | $2,527 | $9,373 |
| Total | $347,637 | $558,014 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Niagen Bioscience, Inc. DEF 14A filed April 29, 2026, accession 0001386570-26-000022, and prior-year filings.
How this page was built: the Niagen Bioscience, Inc. filed document, accession 0001386570-26-000022. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 19,691 | — | $5.48 |
| Option | 40,047 | — | $2.97 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Niagen Bioscience, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Niagen Bioscience discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $160,000 | $0 | $0 | $160,000 |
Per the Potential Payments Upon Termination or Change in Control table in Niagen Bioscience, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Niagen Bioscience’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Robert Fried | Chief Executive Officer | $8,381,900 |
| Ozan Pamir | Chief Financial Officer | $716,475 |
| Carlos Lopez · this page | SVP, General Counsel | $558,014 |
Carlos Lopez's compensation dossier, Niagen Bioscience
You have read Carlos Lopez's totals and holdings. The dossier adds each equity grant Niagen Bioscience disclosed for Carlos Lopez and Niagen Bioscience's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Niagen Bioscience compensation record
free company briefThis page is one person within Niagen Bioscience's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Niagen Bioscience's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Niagen Bioscience's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.